Supergenics Share Price

SGBHD

MYL03033O007

Biotechnology & Medical Research

Market Closed - BURSA MALAYSIA 02:20:01 30/12/2025 pm IST			5-day change	1st Jan Change
0.2500 ^MYR	+21.95%		-.--%	-

29/08	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2026	CI
30/04	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI

Supergenics Berhad is a Malaysia-based management and investment holding company. The Company operates through three segments: Integrated Turnkey Solutions, Biomedical, and Investment Holding. Its Integrated Turnkey Solutions segment is engaged in the provision of integrated turnkey solutions for the related development of cleanrooms and the provision of related maintenance services. Its Biomedical segment is engaged in the provision of administrative health care services, operating medical laboratories, and developing regenerative wellness products. The Company provides laboratory services, including storage and handling of stem cell samples. Its services include stem cells, mesenchymal stem cells (MSC), natural killer (NK) cells, exosomes, and MSC exosomes. Its subsidiaries include Supergenics Solution Sdn. Bhd., Supergenics Life Science Sdn. Bhd., Supergenics Therapeutic Sdn. Bhd., Supergenics Bio Agro Sdn. Bhd., Supergenics Stembank Sdn. Bhd., and Supergenics Global Sdn. Bhd.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
SGBHD Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	2.91Cr 71.25L 62.67L 59.08L 53.9L 1.01Cr 68Cr 1.02Cr 7.09Cr 2.75Cr 35Cr 2.68Cr 2.62Cr 113.27Cr	P/E 2024	-9.45x	P/E 2025	-8.61x
Enterprise Value	3.25Cr 79.56L 69.98L 65.97L 60.19L 1.13Cr 76Cr 1.13Cr 7.92Cr 3.07Cr 39Cr 2.99Cr 2.92Cr 126.48Cr	EV / Sales 2024	13.9x	EV / Sales 2025	5.78x
Free-Float	41.6%	Yield 2024 *	-	Yield 2025	-

29/08	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2026	CI
30/04	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI
27/02	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05/12	Supergenics Seeks 6-Month Extension to Complete Private Placement of Shares	MT
29/25/29	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/25/27	Supergenics fixes issue price at 0.27 RGT per share	RE
12/25/12	Supergenics Berhad Announces the Redesignation of Lau Meng Hong from Executive Director to Non Independent and Non Executive Director, Effective August 12, 2025	CI
21/25/21	Supergenics Berhad Announces Change of Registered Office Address	CI
28/25/28	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2024	CI
30/24/30	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2024	CI
02/24/02	Supergenics Seeks More Time to Complete Private Share Placement	MT
29/24/29	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/24/29	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI

1 year	0.2	0.25
3 years	0.15	0.6
5 years	0.15	0.6
10 years	0.15	0.6

Manager	Title	Age	Since
Bii Chau Tan CEO	Chief Executive Officer	48	24/04/2019
Yuet Chyn Wong SEC	Corporate Secretary	-	02/06/2022

Director	Title	Age	Since
Bii Chau Tan BRD	Director/Board Member	48	24/04/2019
Fun Kim Ng BRD	Director/Board Member	60	24/04/2019
Kiat Yang Chan BRD	Director/Board Member	46	28/01/2022

Supergenics Share Price

Stocks

SGBHD

MYL03033O007

Biotechnology & Medical Research

Valuation: Supergenics

Chart: Supergenics

Latest news: Supergenics

Quotes and Performance

Price Extremes

Managers and Directors: Supergenics

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUPERGENICS	+21.95%	-.--%	-16.67%	+8.70%	71.35L
LONZA GROUP AG	+1.46%	+5.87%	+5.75%	+33.71%	4.76TCr
IQVIA HOLDINGS INC.	+2.67%	+2.07%	+51.74%	+38.37%	4.41TCr
BEONE MEDICINES AG	-1.38%	+1.84%	+9.13%	+88.88%	4.15TCr
REVOLUTION MEDICINES, INC.	+4.78%	+1.48%	+359.03%	+566.20%	4.09TCr
CELLTRION, INC.	-0.62%	+0.11%	+1.12%	+46.02%	2.97TCr
MEDPACE HOLDINGS, INC.	+0.56%	+0.88%	+24.79%	+155.71%	1.72TCr
EUROFINS SCIENTIFIC SE	+2.05%	+1.09%	+25.56%	+41.67%	1.51TCr
ASCENDIS PHARMA A/S	+3.39%	-3.49%	-	-	1.47TCr
TEMPUS AI, INC.	+7.38%	+2.34%	+3.80%	-	1.38TCr
Average	+4.22%	+0.86%	+51.58%	+122.41%	2.64TCr
Weighted average by Cap.	+1.89%	+1.36%	+74.09%	+147.49%

	2024	2025
Net sales	53.22L 13.03L 11.46L 10.8L 10L 18.43L 13Cr 18.57L 1.3Cr 50.23L 6.36Cr 48.91L 47.85L 21Cr	56.25L 13.77L 12.11L 11.42L 10.42L 19.48L 13Cr 19.63L 1.37Cr 53.09L 6.73Cr 51.7L 50.58L 22Cr
Net income	-72.81L -17.82L -15.68L -14.78L -13.48L -25.21L -17Cr -25.41L -1.77Cr -68.72L -8.71Cr -66.91L -65.46L -28Cr	-33.66L -8L -7L -7L -6L -11.66L -7.91Cr -11.75L -81.97L -31.77L -4.02Cr -30.93L -30.26L -13Cr
Net Debt	44.77L 10.96L 10L 9L 8L 15.5L 11Cr 15.62L 1.09Cr 42.25L 5.35Cr 41.14L 40.25L 17Cr	33.94L 8L 7L 7L 6L 11.75L 7.97Cr 11.85L 82.67L 32.03L 4.06Cr 31.19L 30.52L 13Cr